SUN PHARMACEUTICAL INDUSTRIES INC: Drug Recall
Recall #D-0262-2023 · 01/13/2023
Class II: Risk
Recall Details
- Recall Number
- D-0262-2023
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- SUN PHARMACEUTICAL INDUSTRIES INC
- Status
- Terminated
- Date Initiated
- 01/13/2023
- Location
- Princeton, NJ, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- Lot # HAC3120A: 6912 Bottles; Lot # HAC3121A: 6792 Bottles; Lot # HAC4460A: 6816 Bottles; Lot # HAD0365A: 6744 Bottles; Lot # HAD1452A: 6840 Bottles
Reason for Recall
Failed Impurity (Deacetyl Diltiazem Hydrochloride) specification during stability testing and failed dissolution testing at FDA laboratory.
Product Description
Diltiazem Hydrochloride Extended-Release Capsules, USP, 360 mg; Rx only; 90-count bottles, Manufactured by: Sun Pharmaceutical Industries Ltd. Halol-Baroda Highway, Halol-389350, Gujarat, India; Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, NDC 47335-679-81
Distribution Pattern
Nationwide in the U.S.
Other Recalls by SUN PHARMACEUTICAL INDUSTRIES INC
- Class III: Low Risk 01/27/2026
- Class III: Low Risk 12/30/2025
- Class III: Low Risk 11/26/2025
- Class II: Risk 10/28/2025
- Class II: Risk 10/28/2025
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.